Ocumension Therapeutics
HKEX:1477

Watchlist Manager
Ocumension Therapeutics Logo
Ocumension Therapeutics
HKEX:1477
Watchlist
Price: 4.41 HKD 0.46% Market Closed
Market Cap: 3.6B HKD
Have any thoughts about
Ocumension Therapeutics?
Write Note

Ocumension Therapeutics
Unrealized Security Profit/Loss

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Ocumension Therapeutics
Unrealized Security Profit/Loss Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Unrealized Security Profit/Loss CAGR 3Y CAGR 5Y CAGR 10Y
Ocumension Therapeutics
HKEX:1477
Unrealized Security Profit/Loss
ÂĄ154.8m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
H
Hansoh Pharmaceutical Group Company Ltd
HKEX:3692
Unrealized Security Profit/Loss
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Zhangzhou Pientzehuang Pharmaceutical Co Ltd
SSE:600436
Unrealized Security Profit/Loss
ÂĄ45m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Jiangsu Hengrui Pharmaceuticals Co Ltd
SSE:600276
Unrealized Security Profit/Loss
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Yunnan Baiyao Group Co Ltd
SZSE:000538
Unrealized Security Profit/Loss
-ÂĄ61.8m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
S
Sichuan Biokin Pharmaceutical Co Ltd
SSE:688506
Unrealized Security Profit/Loss
-ÂĄ313.1k
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Ocumension Therapeutics
Glance View

Market Cap
3.6B HKD
Industry
Pharmaceuticals

Ocumension Therapeutics engages in the identification, development, and commercialization of ophthalmic therapies. The company is headquartered in Suzhou, Jiangsu. The company went IPO on 2020-07-10. Its main products include OT-401 (YUTIQ), OT-1001 (ZERVIATE), OT-502 (DEXYCU), OT-301 (NCX 470), OT-101 and OT-202, among others. The firm conducts its businesses in the domestic market.

Intrinsic Value
5.8 HKD
Undervaluation 24%
Intrinsic Value
Price

See Also

What is Ocumension Therapeutics's Unrealized Security Profit/Loss?
Unrealized Security Profit/Loss
154.8m CNY

Based on the financial report for Dec 31, 2023, Ocumension Therapeutics's Unrealized Security Profit/Loss amounts to 154.8m CNY.

Back to Top